Physician profile
Claudia I Vidal
NPI 1790944742
$3,819.99
in general payments reported to CMS, 2019-2025
23 companies · $984 in 2025
The $984 reported for 2025 was more than what 91% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $91.17 · 2021: $204 · 2022: $631 · 2023: $794 · 2024: $991 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $564.74 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $460.29 | 2021-2025 | |
| Lilly USA, LLC | $381.60 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $346.12 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $335.79 | 2019-2025 | Adbry |
| Amgen INC. | $326.29 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $310.18 | 2022-2025 | Opzelura |
| Ucb, INC. | $245.01 | 2020-2025 | Bimzelx |
| Genzyme Corporation | $180.64 | 2019-2025 | |
| Janssen Biotech, INC. | $147.16 | 2022-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.62 | 2022-2025 | Spevigo |
| Galderma Laboratories, L.P. | $97.15 | 2024-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.69 | 2019-2023 | Jublia |
| Abbvie INC. | $43.50 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $33.61 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $26.27 | 2019 | |
| Merck Sharp & Dohme LLC | $26.10 | 2025 | Keytruda |
| Epi Health, LLC | $23.57 | 2022 | |
| Genentech USA, INC. | $21.75 | 2022 | |
| Roche Diagnostics Corporation | $17.65 | 2019 | |
| Biofrontera INC. | $17.22 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.54 | 2022 | |
| Intuitive Surgical, INC. | $7.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Vidal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.